24/7 Market News Snapshot 20 December, 2024 – AETHLON MEDICAL INC (NASDAQ:AEMD)

December 20, 2024

DENVER, Colo., 20 December, 2024 (247marketnews.com) – (NASDAQ:AEMD) are discussed in this article.
Aethlon Medical Inc. has captured market attention, trading at $0.588 in the pre-market session, signaling a remarkable 35.67% increase from the previous close of $0.433. With a substantial trading volume of 6.57 million shares, investor interest appears to be intensifying, likely influenced by recent advancements and market speculations surrounding the company’s innovative therapeutics. Technical indicators reflect further growth potential as the stock nears critical resistance levels, prompting investors to closely monitor AEMD’s progress.

Simultaneously, Aethlon Medical is responding to an uptick in inquiries regarding its investigational Hemopurifier device amid rising concerns about H5N1 avian influenza. The emergence of outbreaks, including reports of Bird Flu affecting various animal species and potential human infections, has intensified the demand for effective treatment solutions. The device, designed to remove enveloped viruses like H5N1 from the bloodstream, employs advanced plasma separation and size exclusion techniques, effectively targeting harmful pathogens while preserving blood components.

Early studies conducted with Battelle laboratories have shown promising results, demonstrating that a scaled-down version of the Hemopurifier can eliminate up to 99% of the H5N1 virus within six hours of treatment. Although the device has not yet been employed for H5N1 patients, it has previously demonstrated efficacy in managing severe infections such as hepatitis C, HIV, and critically ill COVID-19 cases. The FDA has granted “breakthrough” designation to the Hemopurifier, highlighting its potential as a life-saving treatment for serious viral infections lacking approved therapies.

Aethlon Medical is actively monitoring the evolving landscape of H5N1 infections and is poised to collaborate with healthcare providers and regulatory agencies to explore the device’s therapeutic applications. As the healthcare sector seeks innovative responses to viral challenges, Aethlon Medical stands committed to advancing medical technology to improve patient outcomes and enhance treatment options. Further updates on the company’s initiatives are anticipated as the situation develops.

Related news for (AEMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.